MeiraGTx Holdings plc (MGTX) Stock

MeiraGTx Holdings plc (MGTX) is a Healthcare stock trading at $11.31 (as of 2026-06-18), with a market capitalization of $986.29M and a trailing P/E of -7.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

MeiraGTx Holdings plc is a clinical-stage gene therapy company developing treatments for patients with serious diseases. Its pipeline includes programs for ocular conditions such as inherited retinal disorders and for xerostomia after radiation for head and neck cancer, as well as degenerative and neurodegenerative diseases, including Parkinson’s and amyotrophic lateral sclerosis.

Valuation — source: SEC EDGAR (first-party)
Price	$11.31
Market Cap	$986.29M
P/E Ratio	-7.6
EV / EBITDA	-10.5
Price / Book	-18.03
Price / Sales	13.14
DCF Value (model)	$-9.65
DCF Upside vs Price	-185.3%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$81.39M
Net Margin	-140.3%
Return on Equity	207.4%
Current Ratio	0.55
Revenue Growth (YoY)	144.6%
EPS Growth (YoY)	-33.0%
FCF Growth (YoY)	-54.1%

Financial Health — source: SEC EDGAR
Altman Z-Score	-3.72 (distress)

Valuation vs Sector & Industry
Stock P/E	-7.6
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-136.6%
vs Industry	-145.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Sanofi ($105.63M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Alexandria Forbes
Employees	375
Country	US
IPO Date	2018-06-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.